Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis

被引:34
作者
Lord, Sarah J. [1 ]
Marinovich, M. Luke [2 ]
Patterson, Jilian A. [3 ]
Wilcken, Nicholas [4 ]
Kiely, Belinda E. [1 ]
Gebski, Val [1 ]
Crossing, Sally [5 ]
Roder, David M. [6 ]
Gattellari, Melina [7 ]
Houssami, Nehmat [2 ]
机构
[1] Univ Sydney, Natl Hlth & Med Res Council, Clin Trials Ctr, Sydney, NSW 2006, Australia
[2] Univ Sydney, Sch Publ Hlth, Screening & Test Evaluat Program, Sydney, NSW 2006, Australia
[3] NSW Minist Hlth, Sydney, NSW, Australia
[4] Univ Sydney, Westmead Hospital, Sydney, NSW 2006, Australia
[5] Canc Voices NSW, Sydney, NSW, Australia
[6] Univ S Australia, Adelaide, SA 5001, Australia
[7] Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia
基金
英国医学研究理事会;
关键词
REGISTRY DATA; HAZARD RATES; CHEMOTHERAPY; RECURRENCE; DOCETAXEL; TAMOXIFEN; SURVIVAL; THERAPY;
D O I
10.5694/mja12.10026
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To estimate the incidence of metastatic breast cancer (MBC) in Australian women with an initial diagnosis of non-metastatic breast cancer. Design, setting and participants: A population-based cohort study of all women with non-metastatic breast cancer registered on the New South Wales Central Cancer Register (CCR) in 2001 and 2002 who received care in a NSW hospital. Main outcome measures: 5-year cumulative incidence of MBC; prognostic factors for MBC. Results: MBC was recorded within 5 years in 218 of 4137 women with localised node-negative disease (5-year cumulative incidence, 5.3%; 95% CI, 4.6%-6.0%): and 455 of 2507 women with regional disease (5-year cumulative incidence, 18.1%; 95% CI, 16.7%-19.7%). The hazard rate for developing MBC was highest in the second year after the initial diagnosis of breast cancer. Determinants of increased risk of MBC were regional disease at diagnosis, age less than 50 years and living in an area of lower socio-economic status. Conclusions: Our Australian population-based estimates are valuable when communicating average MBC risks to patients and planning clinical services and trials. Women with node-negative disease have a tow risk of developing MBC, consistent with outcomes of adjuvant clinical trials. Regional disease at diagnosis remains an important prognostic factor.
引用
收藏
页码:688 / 692
页数:5
相关论文
共 24 条
[1]  
[Anonymous], MEAS REM ACC REM IND
[2]  
Breast Cancer Action Group, 2007, DIAGN TREATM
[3]   Adjuvant therapy, not mammographic screening, accounts for most of the observed breast cancer specific mortality reductions in Australian women since the national screening program began in 1991 [J].
Burton, Robert C. ;
Bell, Robin J. ;
Thiagarajah, Geetha ;
Stevenson, Christopher .
BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (03) :949-955
[4]   Bridging Gaps, Expanding Outreach: Metastatic Breast Cancer Advocacy Working Group Consensus Report [J].
Caplan, Elyse S. ;
Englander, Linda ;
Hamzah, Ednin ;
Herzberg, Vitoria ;
Howery, Carla ;
Kelly, Pat ;
Knox, Susan ;
Lewis, Stacy ;
Manthorne, Jackie ;
Mijares de Capin, Alejandra ;
Paradis, Jennifer ;
Reed, Liz ;
Romeo, Lilla ;
Sheehan, Donna ;
Spicer, Pat ;
Weiss, Marisa .
BREAST, 2009, 18 (05) :273-275
[5]  
Centre for Health Record Linkage, 2011, QUAL ASS REP 2011
[6]   Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data [J].
Coleman, M. P. ;
Forman, D. ;
Bryant, H. ;
Butler, J. ;
Rachet, B. ;
Maringe, C. ;
Nur, U. ;
Tracey, E. ;
Coory, M. ;
Hatcher, J. ;
McGahan, C. E. ;
Turner, D. ;
Marrett, L. ;
Gjerstorff, M. L. ;
Johannesen, T. B. ;
Adolfsson, J. ;
Lambe, M. ;
Lawrence, G. ;
Meechan, D. ;
Morris, E. J. ;
Middleton, R. ;
Steward, J. ;
Richards, M. A. .
LANCET, 2011, 377 (9760) :127-138
[7]   National Breast Cancer Audit: Overview of invasive breast cancer management [J].
Cuncins-Hearn, Astrid V. ;
Boult, Margaret ;
Babidge, Wendy ;
Zorbas, Helen ;
Villanueva, Elmer ;
Evans, Alison ;
Oliver, David ;
Kollias, James ;
Reeve, Tom ;
Maddern, Guy .
ANZ JOURNAL OF SURGERY, 2006, 76 (08) :745-750
[8]   Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23 [J].
Fisher, B ;
Anderson, S ;
Tan-Chiu, E ;
Wolmark, N ;
Wickerham, DL ;
Fisher, ER ;
Dimitrov, NV ;
Atkins, JN ;
Abramson, N ;
Merajver, S ;
Romond, EH ;
Kardinal, CG ;
Shibata, HR ;
Margolese, RG ;
Farrar, WB .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) :931-942
[9]   Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer [J].
Fisher, B ;
Dignam, J ;
Wolmark, N ;
DeCillis, A ;
Emir, B ;
Wickerham, DL ;
Bryant, J ;
Dimitrov, NV ;
Abramson, N ;
Atkins, JN ;
Shibata, H ;
Deschenes, L ;
Margolese, RG .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (22) :1673-1682
[10]   Quality of diagnosis and procedure coding in ICD-10 administrative data [J].
Henderson, Toni ;
Shepheard, Jennie ;
Sundararajan, Vijaya .
MEDICAL CARE, 2006, 44 (11) :1011-1019